Applied Pharmaceutical Chemistry 2026
Pfizer, Cambridge, MA
Thursday, April 2, 2026
Confirmed speakers for APC 2026
![]() |
Plenary Lecture: Yu-Shan Lin, PhD Professor and Department Chair, Chemistry @ Tufts University Structure Prediction of Cyclic Peptides Via Molecular Dynamics and Machine Learning |
![]() |
Plenary Lecture: Gregory L. Verdine, PhD Ervin Professor of Chemistry, Department of Chemistry & Chemical Biology @ Harvard University The Radicalization of Drug Discovery |
![]() |
Abba Leffler, PhD Senior Principal Scientist, Computational Chemistry @ Schrodinger Talk title TBA
|
![]() |
Anne Marinier, PhD Director of the Discovery Unit, IRIC; Prof. Department of Pharmacology & Physiology, University de Montreal UM171: From Stem Cell Expansion to CoREST Degradation - A Clinical Molecular Glue Story |
![]() |
Ludivine Moine, MSc Principal Scientist @ Blueprint Medicines Design and Synthesis of BLU-654, a Potent and Selective Mutant KIT V654A Inhibitor for the Treatment of imatinib-resistant GIST |
![]() |
Taylor Quinn, PhD Associate Principal Scientist @ AstraZeneca AI in drug discovery (developing the Cbl-b inhibitors for cancer immunotherapy)- Title TBA |
![]() |
Rebecca Swett, PhD Director of Computational Chemistry Innovation @ X-Chem Chemomics Applied: What leveraging a complete DEL dataset looks like in practice |
![]() |
Momar Toure, PhD Director, Medicinal Chemistry @ MOMA Therapeutics Discovery and Optimization of a Novel Covalent WRN Helicase Inhibitor Series
|
![]() |
Murray Wan, PhD Principal Scientist @ Mariana Oncology a Novartis Company ETN029:Discovery of a DLL3-targeted Radioligand Therapy for the Treatment of SCLC and Beyond
|
![]() |
Elsie Yu, PhD Associate Principal Scientist @ Merck IL4i1 Inhibitors from Target Validation Through to First-In-Human Studies in Cancer Patients |
Join our LinkedIn Group




















